Price alert —
Sign in to get a one-time email the moment INSM crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · INSM
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.3B | $-0.2B | $-0.2B | $-0.2B | -53.5% | -65.5% |
| 2025-12-31 | $0.3B | $-0.3B | $-0.2B | $-0.3B | -124.5% | -94.6% |
| 2025-09-30 | $0.1B | $-0.4B | $-0.3B | $-0.2B | -260.0% | -183.6% |
| 2025-06-30 | $0.1B | $-0.3B | $-0.3B | $-0.2B | -299.5% | -236.4% |
| 2025-03-31 | $0.1B | $-0.3B | $-0.2B | $-0.3B | -276.4% | -247.6% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare INSM vs peers
Line INSM up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with INSM
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-07 | -0.76 | -1.00 | +23.9% | -3.5% |
| 2026-02-19 | -1.54 | -1.17 | -31.9% | +2.4% |
| 2025-10-30 | -1.75 | -1.37 | -27.8% | -2.4% |
| 2025-08-07 | -1.70 | -1.31 | -29.6% | +0.2% |
| 2025-05-08 | -1.42 | -1.36 | -4.2% | -0.8% |
| 2025-02-20 | -1.32 | -1.16 | -13.3% | -3.0% |
| 2024-10-31 | -1.27 | -1.25 | -1.9% | +1.6% |
| 2024-08-08 | -1.94 | -1.23 | -58.2% | +3.0% |
| 2024-05-09 | -1.06 | -1.20 | +11.5% | -1.6% |
| 2024-02-22 | -1.28 | -1.13 | -13.3% | +0.5% |
| 2023-10-26 | -1.11 | -1.11 | +0.2% | -6.5% |
| 2023-08-03 | -1.78 | -1.12 | -58.9% | -0.7% |
| 2023-05-04 | -1.17 | -1.10 | -6.4% | -0.8% |
| 2023-02-23 | -1.21 | -1.02 | -18.2% | -1.5% |
| 2022-10-27 | -1.09 | -0.87 | -24.9% | +3.1% |
| 2022-08-04 | -0.80 | -0.89 | +10.6% | +10.7% |
| 2022-05-05 | -0.80 | -0.87 | +8.1% | -10.5% |
| 2022-02-17 | -0.95 | -0.86 | -10.2% | -3.2% |
| 2021-10-28 | -0.96 | -0.78 | -23.1% | +1.9% |
| 2021-08-05 | -0.91 | -0.88 | -2.7% | +1.1% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| INSM ★ | $23B | — | 814.4 | 28.6 | -24.2 | 33.3 | 81.8% | 229.6% | — | -2.58% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 53.92%
| Holder | Shares | % out |
|---|---|---|
| JPMORGAN CHASE & CO | 24,150,499 | 11.14% |
| Darwin Global Management, Ltd. | 16,805,184 | 7.75% |
| Blackrock Inc. | 16,678,146 | 7.69% |
| FMR, LLC | 13,160,167 | 6.07% |
| Vanguard Portfolio Management LLC | 10,371,802 | 4.79% |
| Vanguard Capital Management LLC | 9,642,131 | 4.45% |
| Baker Bros. Advisors, LP | 7,421,111 | 3.42% |
| Artisan Partners Limited Partnership | 6,527,301 | 3.01% |
| Invesco Ltd. | 6,512,889 | 3.00% |
| Shaw D.E. & Co., Inc. | 5,625,825 | 2.60% |
Insider activity · 90d
0 buys / 5 sells · ratio 0.0 · Finnhub
- Lewis William M 4,440
- Lewis William M 6,260
- Lewis William SELL 259,058 @ $118.52
- Lewis William SELL 262,417 @ $117.62
- Lewis William SELL 264,752 @ $116.55
- Lewis William M 269,757 @ $17.16
- Lewis William M 265,317 @ $30.46
- Flammer Martina M.D. M 4,358
- Flammer Martina M.D. M 23,835
- Flammer Martina M.D. SELL 60,486 @ $110.60
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-16 | 8-K | view · |
| 4 | 2026-07-10 | FORM 4 | view · |
| 4 | 2026-07-08 | FORM 4 | view · |
| 4 | 2026-06-26 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-10 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-05-22 | FORM 4 | view · |
| 4 | 2026-05-20 | FORM 4 | view · |
| 4 | 2026-05-15 | FORM 4 | view · |
| 4 | 2026-05-15 | FORM 4 | view · |
| 4 | 2026-05-15 | FORM 4 | view · |
| 4 | 2026-05-15 | FORM 4 | view · |
| 4 | 2026-05-15 | FORM 4 | view · |
| 4 | 2026-05-15 | FORM 4 | view · |
| 4 | 2026-05-15 | FORM 4 | view · |
| 4 | 2026-05-15 | FORM 4 | view · |
| 4 | 2026-05-15 | FORM 4 | view · |
| 4 | 2026-05-15 | FORM 4 | view · |
| 4 | 2026-05-15 | FORM 4 | view · |
| 8-K | 2026-05-15 | 8-K | view · |
| 4 | 2026-05-13 | FORM 4 | view · |
| 8-K | 2026-05-07 | 8-K | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| 4 | 2026-05-06 | FORM 4 | view · |
| 4 | 2026-04-17 | FORM 4 | view · |
| 4 | 2026-04-08 | FORM 4 | view · |
| 8-K | 2026-04-07 | 8-K | view · |
| 4 | 2026-04-03 | FORM 4 | view · |
| DEF 14A | 2026-04-01 | DEF 14A | view · |
| 4 | 2026-03-31 | FORM 4 | view · |
| 8-K | 2026-03-23 | 8-K | view · |
| 4 | 2026-03-20 | FORM 4 | view · |
| 4 | 2026-03-05 | FORM 4 | view · |
| 4 | 2026-03-05 | FORM 4 | view · |
| 4 | 2026-02-27 | FORM 4 | view · |
| 4 | 2026-02-25 | FORM 4 | view · |
| 4 | 2026-02-25 | FORM 4 | view · |
| 4 | 2026-02-23 | FORM 4 | view · |
| 10-K | 2026-02-19 | 10-K | view · |
| 8-K | 2026-02-19 | 8-K | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-01-22 | FORM 4 | view · |
| 4 | 2026-01-13 | FORM 4 | view · |
| 4 | 2026-01-13 | FORM 4 | view · |
| 8-K | 2026-01-09 | 8-K | view · |
| 4 | 2026-01-08 | FORM 4 | view · |
| 4 | 2026-01-08 | FORM 4 | view · |
About INSM
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 cl…
Options picks · INSM
ITM + OTM ideas from the latest scanLoading…
Congress trades · INSM
STOCK Act disclosuresLoading…
SEC filings & insiders · INSM
EDGAR · liveLoading…
Holders · INSM
Institutions & insider activityLoading…